[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598159":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":32,"locations":42,"responsibleParty":57,"collaborators":24,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":24,"enrollmentInfo":70,"targetDuration":24,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":45,"whyStopped":24,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Hospital Nossa Senhora da Conceicao","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Titrated group","EXPERIMENTAL","The titrated group will follow the vasopressin weaning protocol used in the DOVSS study (reduction of 0.01 U\u002Fmin per hour).",[13],"Other: Titrated weaning of vasopressin.",{"label":15,"type":16,"description":17,"interventionNames":18},"Abrupt group","ACTIVE_COMPARATOR","The abrupt group will discontinue the vasopressin infusion at the time of randomization, without dose titration.",[19],"Other: Abrupt weaning of vasopressin.",[21,25],{"type":6,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"Titrated weaning of vasopressin.",[9],null,{"type":6,"name":26,"description":17,"armGroupLabels":27,"otherNames":24},"Abrupt weaning of vasopressin.",[15],[29],{"name":30,"affiliation":5,"role":31},"Cássio Mallmann, Critical Care Physician, MS","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},"Wagner Luis Nedel, Critical Care Physician, PhD","CONTACT","55 51 999547554","wagnernedel@gmail.com",{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},"Rafael Barberena Moraes, Critical Care Physician, PhD","55 51 996971855","rbmoraes@hcpa.edu.br",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":24},"Hospital Nossa Senhora da Conceição","RECRUITING","Porto Alegre","Rio Grande do Sul","91350200","Brazil","BR",{"type":52,"coordinates":53},"Point",[54,55],-51.23019,-30.03283,{"lat":55,"lon":54},{"type":31,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Cássio Mallmann","Critical Care Physician, MS","100598159","phase-3-weaning-approaches-for-vasopressin-in-sepsis-100598159",false,"NCT07067866","Weaning Approaches for Vasopressin in Sepsis","Weaning Approaches for Vasopressin in Sepsis - a Randomized Controlled Trial of Titrated Versus Abrupt Discontinuation During Stabilization of Septic Shock - WAVES Trial","WAVES","Inclusion Criteria:\n\n* Age over 18 years\n* Admitted to the Intensive Care Unit\n* Patients with vasopressor dependent sepsis\n* Receiving combined norepinephrine and vasopressin therapy\n\nExclusion Criteria:\n\n* Withdrawal\u002Freduction of vasopressin related to a plan of treatment limitation or palliative care\n* Withdrawal\u002Freduction of vasopressin associated with the initiation of adrenaline or any other vasopressor","ALL","18 Years",{"count":71,"type":72},82,"ESTIMATED","INTERVENTIONAL",[75],"PHASE3","In this study, we aim to evaluate the incidence of hypotension during vasopressin weaning by comparing two methods - titrated reduction versus abrupt withdrawal - through the conduct of a randomized clinical trial.",[78],"Septic Shock",[80,81,82],"vasopressin","septic shock","vasopressor weaning","2025-12-29",{"date":85,"type":86},"2026-01-02","ACTUAL",{"date":88,"type":86},"2025-10-01",{"date":90,"type":72},"2028-10-01",{"name":5,"class":6},1]